News | February 04, 2022
Lupin Q3FY22 PAT at Rs 545.52 cr.
Lupin has reported consolidated financial results for the period ended December 31, 2021
Lupin has reported consolidated financial results for the period ended December 31, 2021
Sun Pharma’s Q3FY22 operational performance was in line with I-direct estimates with sustained momentum and good growth across businesses
Ascent Meditech has set benchmarks in introducing pain management products in India. The company has embarked on a new marketing campaign as it plans to enter new markets. Rajiv Mistry, Founder & Managing Director, Ascent Group shares his perspective with Thomas C Thottathil on the road ahead for the company and industry
Dr. Reddy’s included in S&P Global’s Sustainability Yearbook for the 2nd year and Bloomberg Gender-Equality Index for the 5th year in a row
The acquisition will allow Dr. Reddy's to build on Nimbus Health's strengths and introduce medical cannabis-based medicines as a promising treatment option for patients
ICICI Direct analysis of Dr Reddy’s Q3FY22 results
ICICI Direct’s analysis of Cipla’s Q3FY22 results
The company develops sustainable botanical materials for agricultural and pharmaceutical applications
Cipla announced its unaudited consolidated financial results for quarter ended December 31st, 2021.
_256_384.jpg)
The oversubscribed round was led by New York-based HOF Capital and welcomed new investors including Headline, East Ventures, MS&AD Ventures, DG Daiwa Ventures, Pioneer Fund, as well as existing investor Insignia Ventures Partners
Subscribe To Our Newsletter & Stay Updated
